The article, 'Innovators in AI Drug Repurposing: Pioneering AI in the Pharmaceutical Industry,' showcases BostonGene at the forefront of innovation by leading in both geographical reach and application diversity. BostonGene's groundbreaking contributions to the pharmaceutical industry, driven by in artificial intelligence (AI)-based and advanced bioinformatics solutions, with the company holding more than 200 patents, solidified its leadership position in total patent count.
AI-driven drug repurposing, a cutting-edge approach to drug discovery and development, leverages AI-powered machine learning algorithms to identify existing drugs that may have efficacy in diseases or disease subtypes different from the original intended patient population. This innovative approach may significantly reduce the time and cost of bringing new therapies to market. BostonGene's AI-driven solutions have already been instrumental in accelerating drug discovery and development processes. The company's proprietary platform utilizes the power of AI to analyze vast datasets, including genetic, clinical, and molecular information, to uncover novel uses for existing therapeutics. BostonGene's mission is to improve patient outcomes by providing customized, cost-effective solutions with fast turnaround times, to get the right drugs to the right patients.
'We are honored to be recognized as innovators in AI drug repurposing,' said
BostonGene's contributions to AI-driven drug repurposing align with its broader mission of advancing precision medicine by tailoring treatments to individual patients. By leveraging AI and bioinformatics, BostonGene unlocks the full potential of existing drugs while reducing the risks and costs associated with traditional drug development.
Pharmaceutical Technology, part of the
About
BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene's service model provides customized client solutions using a multi-omic approach prioritized for real-world impact including optimized standard-of-care therapies, accelerated research and cost-effective, measurable results. BostonGene's tests reveal key drivers of each patient's unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene's tests generate a personalized roadmap for therapeutic decision-making for each patient.
Contact:
Tel: +1-617-283-2285
Email: Erin.Oreilly@BostonGene.com
(C) 2024 Electronic News Publishing, source